Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)

Palifermin, a recombinant human keratinocyte growth factor, was tested for potential benefits on acute graft-versus-host disease (GVHD) and hematopoietic recovery in allogeneic hematopoietic stem cell transplantation (HSCT) recipients. This randomized, double-blind, placebo-controlled, dose-escalati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2006-11, Vol.108 (9), p.3216-3222
Hauptverfasser:	Blazar, Bruce R., Weisdorf, Daniel J., DeFor, Todd, Goldman, Anne, Braun, Thomas, Silver, Samuel, Ferrara, James L.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Bone marrow, stem cells transplantation. Graft versus host reaction Child Child, Preschool Female Fibroblast Growth Factor 7 - therapeutic use Fibroblast Growth Factor 7 - toxicity Graft vs Host Disease - prevention & control Hematologic Neoplasms - mortality Hematologic Neoplasms - therapy Hematopoietic Stem Cell Transplantation Humans Male Medical sciences Middle Aged Placebos Survival Analysis Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation, Homologous - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!